Scientific evidence for health effects attributed to the consumption of probiotics and prebiotics: An update for current perspectives and future challenges

British Journal of Nutrition

Volumn 114, Issue 12, 2015, Pages 1993-2015

  Martinez, Rafael Chacon Ruiz ^a   Bedani, Raquel ^a   Saad, Susana Marta Isay ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Bifidobacterium; Health effects; Inulin; Lactobacillus; Prebiotics; Probiotics

Indexed keywords

LACTIC ACID; LACTULOSE; PREBIOTIC AGENT; PROBIOTIC AGENT; YOGHURT;

ALLERGIC REACTION; ARTICLE; BIFIDOBACTERIUM; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; DIET SUPPLEMENTATION; DIET THERAPY; FEEDING BEHAVIOR; FOOD INTAKE; FOOD SAFETY; HALITOSIS; HELICOBACTER INFECTION; HUMAN; IMMUNE SYSTEM; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; INTESTINE INFECTION; IRRITABLE COLON; LACTIC ACID BACTERIUM; LACTOBACILLUS; MICROFLORA; NONHUMAN; OSTEOPOROSIS; PEPTOCLOSTRIDIUM DIFFICILE; PERIODONTAL DISEASE; RELIABILITY; RESPIRATORY TRACT INFECTION; RISK FACTOR; RISK REDUCTION; UROGENITAL TRACT INFECTION; EUROPE; PHYSIOLOGY; PREVENTIVE MEDICINE;

EUROPE; FOOD SAFETY; HUMANS; IMMUNE SYSTEM; MICROBIOTA; PREBIOTICS; PREVENTIVE MEDICINE; PROBIOTICS;

EID: 84949313802     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114515003864     Document Type: Article

References (254)

1. Laparra JP & Sanz Y (2010) Interactions of gut microbiota with functional food components and nutraceuticals. Pharmacol Res 61, 219-225.
2. Aureli P, Capurso L, Castellazzi AM, et al. (2011) Probiotics and health: an evidence-based review. Pharmacol Res 63, 366-376.
3. Ley RE, Lozupone CA, Hamady M, et al. (2008) Worlds within worlds: evolution of the vertebrate gut microbiota. Nat Rev Microbiol 6, 776-788.
4. Booijink CCGM, Zoetendal EG, Kleerebezem M, et al. (2007) Microbial communities in the human small intestine-coupling diversity to metagenomics. Future Microbiol 2, 285-295.
5. Zoetendal EG, Rajilic-Stojanovic M & De Vos WM (2008) High throughput diversity and functionality analysis of the gastrointestinal tract microbiota. Gut 57, 1605-1615.
6. Tap J, Mondot S, Levenez F, et al. (2009) Towards the human intestinal microbiota phylogenetic core. Environ Microbiol 11, 2574-2584.
7. Phillips ML (2009) Gut reaction: environmental effects on the human microbiota. Environ Health Perspect 117, 198-205.
8. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. (2009) A core gut microbiome in obese and lean twins. Nature 457, 480-484.
9. Qin J, Li R, Raes J, et al. (2010) A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59-65.
10. Tremaroli V & Bäckhed F (2012) Functional interactions between the gut microbiota and host metabolism. Nature 489, 242-249.
11. Zhang J, Guo Z, Xue Z, et al. (2015) A phylo-functional core of gut microbiota in healthy young Chinese cohorts across lifestyles, geography and ethnicities. ISME J 9, 1979-1990.
12. Hill MJ (1997) Intestinal flora and endogenous vitamin synthesis. Eur J Cancer Prev 6, 43-45.
13. Pryde SE, Duncan SH & Hold GL (2002) The microbiology of butyrate formation in the human colon. FEMS Microbiol Lett 217, 133-139.
14. Tappenden KA & Deutsch AS (2007) The physiological relevance of the intestinal microbiota-contributions to human health. J Am Coll Nutr 26, 679-683.
15. Resta SC (2009) Effects of probiotics and commensals on intestinal epithelial physiology: implications for nutrient handling. J Physiol 587, 4169-4174.
16. Saulnier DM, Kolida S & Gibson GR (2009) Microbiology of the human intestinal tract and approaches for its dietary modulation. Curr Pharm Des 15, 1403-1414.
17. Round JL & Mazmanian SK (2009) The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 9, 313-323.
18. Scanlan PD, Shanahan F, O'Mahony C, et al. (2006) Cultureindependent analyses of temporal variation of the dominant fecal microbiota and targeted bacterial subgroups in Crohn's disease. J Clin Microbiol 44, 3980-3988.
19. Cani PD & Delzenne NM (2009) The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des 15, 1546-1558.
20. Davis CD & Milner JA (2009) Gastrointestinal microflora, food components and colon cancer prevention. J Nutr Biochem 20, 743-752.
21. Caesar R, Fak F & Bäckhed F (2010) Effects of gut microbiota on obesisty and atherosclerosis via modulation of inflammation and lipid metabolism. J Inter Med 268, 320-328.
22. Gerritsen J, Smidt H, Rijkers GT, et al. (2011) Intestinal microbiota in human health and disease: The impact of probiotics. Genes Nutr 6, 209-240.
23. Ley RE, Peterson DA & Gordon JI (2006) Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 124, 837-848.
24. Ross RP, Mills S, Hill C, et al. (2010) Specific metabolite production by gut microbiota as a basis for probiotic function. Int Dairy J 20, 269-276.
25. Scott KP, Gratz SW, Sheridan PO, et al. (2013) The influence of diet on the gut microbiota. Pharmacol Res 69, 52-60.
26. O'Shea EF, Cotter PD, Stanton C, et al. (2012) Production of bioactive substances by intestinal bacteria as a basis for explaining probiotic mechanisms: bacteriocins and conjugated linoleic acid. Int J Food Microbiol 152, 189-205.
27. Peterson CT, Sharma V, Elmén S, et al. (2015) Immune homeostasis, dysbiosis and therapeutic modulation of the gut microbiota. Clin Exp Immunol 179, 363-377.
28. McNulty NP, Yatsunenko T, Hsiao A, et al. (2011) The impact of a consortium of fermented milk strains on the gut microbiome of gnotobiotic mice and monozygotic twins. Sci Transl Med 3, 106ra106.
29. Rauch M & Lynch SV (2012) The potential for probiotic manipulation of the gastrointestinal microbiome. Curr Opin Biotechnol 23, 192-201.
30. Hill C, Guarner F, Reid G, et al. (2014) The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11, 506-514.
31. Stolaki M, De Vos W, Kleerebezem M, et al. (2012) Lactic acid bacteria in the gut. In Lactic Acid Bacteria: Microbiological and Functional Aspects, pp. 385-401 [S Lahtinen, AC Ouwehand, S Salminen and A Von Wright, editors]. Boca Raton, FL: CRC.
32. Tannock GW (1998) Studies on the intestinal microflora: A prerequisite for the development of probiotics. Int Dairy J 8, 527-533.
33. Kolida S & Gibson GR (2011) Synbiotic in health and disease. Annu Rev Food Sci Technol 2, 373-393.
34. Champagne CP, Ross RP, Saarela M, et al. (2011) Recommendations for viability assessment of probiotics as concentrated cultures and in food matrices. Int J Food Microbiol 149, 185-193.
35. Agência Nacional De Vigilância Sanitária (Brazilian Health Surveillance Agency) (2008) Alimentos com alegações de propriedades funcionais e ou de saúde, novos alimentos/ ingredientes, substâncias bioativas e probióticos: lista de alegações de propriedade funcional aprovadas. Atualizado em julho, 2008. (Foods with allegation of functional and/or health properties, new foods/ingredients, bioactive compounds and probiotics: list of allegations of approved functional properties. Up-dated in 2008) http://www.anvisa.gov. br/alimentos/comissoes/tecno-lista-alega.htm (accessed August 2009).
36. Health Canada (2009) Accepted claims about the nature of probiotic microorganisms in foods. http://www.hc-sc.gc.ca/ fn-an/label-etiquet/claims-reclam/probiotics-claims-allegations-probiotiques-eng.php (accessed October 2014).
37. Ministero della Salute, Commissione unica per la nutrizione e la dietetica (2013) Guidelines on probiotics and prebiotics. http://www.salute.gov.it/imgs/C-17-pubblicazioni-1016-allegato.pdf (accessed October 2014).
38. Lee YK & Salminen S (2009) Handbook of Probiotics, 2nd ed. Hoboken, NJ: John Wiley & Sons.
39. Gibson GR, Probert HM, Van Loo JAE, et al. (2004) Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. Nutr Res Rev 17, 259-275.
40. Gibson GR, Scott KP, Rastall RA, et al. (2010) Dietary prebiotics: current status and new definition. Food Sci Technol Bull: Funct Foods 7, 1-19.
41. Rastall RA (2010) Functional oligosaccharides: application and manufacture. Annu Rev Food Sci Technol 1, 305-339.
42. Roberfroid M (2007) Prebiotic: The concept revisited. J Nutr 137, 830-837.
43. Broekaert WF, Courtin CM, Verbeke K, et al. (2011) Prebiotic and other health-related effects of cereal-derived arabinoxylans, arabinoxylan-oligosaccharides, and xylooligosaccharides. Crit Rev Food Sci Nutr 51, 178-194.
44. Crittenden RG, Morris LF, Harvey ML, et al. (2001) Selection of a Bifidobacterium strain to complement resistant starch in a synbiotic yoghurt. J Appl Microbiol 90, 268-278.
45. Topping DL, Fukushima M & Bird AR (2003) Resistant starch as a prebiotic and synbiotic: state of the art. Proc Nutr Soc 62, 171-176.
46. Figueroa-González I, Quijano G, Ramírez G, et al. (2011) Probiotics and prebiotics-perspectives and challenges. J Sci Food Agric 91, 1341-1348.
47. Topping DL & Clifton PM (2001) Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev 81, 1031-1064.
48. Crittenden R & Playne M (2009) Prebiotics. In Handbook of Probiotics and Prebiotics, pp. 535-581 [YK Lee and S Salminen, editors]. Hoboken, NJ: John Wiley & Sons.
49. Holzapfel WH & Schillinger U (2002) Introduction to pre-and probiotics. Food Res Int 35, 109-116.
50. Puupponen-Pimiä R, Aura AM, Oksman-Caldentey KM, et al. (2002) Development of functional ingredients for gut health. Trends Food Sci Technol 13, 3-11.
51. Mattila-Sandholm T, Myllärinen P, Crittenden R, et al. (2002) Technological challenges for future probiotic foods. Int Dairy J 12, 173-182.
52. Bielecka M, Biedrzycka E & Majkowska A (2002) Selection of probiotics and prebiotics for synbiotics and confirmation of their in vivo effectiveness. Food Res Int 35, 125-131.
53. Sanders ME & Marco ML (2010) Food formats for effective delivery of probiotics. Annu Rev Food Sci Technol 1, 65-85.
54. Rolfe RD (2000) The role of probiotic cultures in the control of gastrointestinal health. J Nutr 130, 396-402.
55. Saad SMI (2006) Probióticos e prebióticos: o estado da arte (Probiotics and prebiotics: The state of the art). Revista Brasileira de Ciências Farmacêuticas 42, 1-16.
56. de Vrese M & Marteau PR (2007) Probiotics and prebiotics: effects on diarrhea. J Nutr 137, 803-811.
57. Saad N, Delattre C, Urdaci M, et al. (2013) An overview of the last advances in probiotic and prebiotic field. LWT-Food Sci Technol 50, 1-16.
58. Floch MH, Walker WA, Madsen K, et al. (2011) Recommendations for probiotic use: 2011 update. J Clin Gastroenterol 45, 168-171.
59. Guandalini S (2011) Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol 45, 149-153.
60. Wolvers D, Antoine JM, Myllyluoma E, et al. (2010) Guidance for substantiating the evidence for beneficial effects of probiotics: prevention and management of infections by probiotics. J Nutr 140, 698-712.
61. Arvola T, Laiho K, Torkkeli S, et al. (1999) Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: A randomized study. Pediatrics 104, e64.
62. Vanderhoof JA, Whitney DB, Antonson DL, et al. (1999) Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J Pediatr 135, 564-568.
63. Marchand J & Vandenplas Y (2000) Microorganisms administered in the benefit of the host: myths and facts. Eur J Gastroenterol Hepatol 12, 1077-1088.
64. Dendukuri N, Costa V, McGregor M, et al. (2005) Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: A systematic review. CMAJ 173, 167-170.
65. Roberfroid M, Gibson GR, Hoyles L, et al. (2010) Prebiotic effects: metabolic and health benefits. Br J Nutr 104, 1-63.
66. Thompson I (2008) Clostridium difficile-associated disease: update and focus on non-antibiotic strategies. Age Ageing 37, 14-18.
67. Kale-Pradhan PB, Jassal HK, et al. (2010) Role of Lactobacillus in the prevention of antibiotic-associated diarrhea: A meta-analysis. Pharmacotherapy 30, 119-126.
68. Hickson M, D'Souza AL, Muthu N, et al. (2007) Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 335, 80.
69. Pozzoni P, Riva A, Bellatore AG, et al. (2012) Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: A single-center, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol 107, 922-931.
70. Gorbach SL (2000) Probiotics and gastrointestinal health. Am J Gastroenterol 95, 14-18.
71. Goldin BR & Gorbach SL (2008) Clinical indications for probiotics: an overview. Clin Infect Dis 46, 96-100.
72. Graul T, Cain AM & Karpa KD (2009) Lactobacillus and bifidobacteria combinations: A strategy to reduce hospitalacquired Clostridium difficile diarrhea incidence and mortality. Med Hypotheses 73, 194-198.
73. Thomas MR, Litin SC, Osmon DR, et al. (2001) Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: A randomized, placebo-controlled trial. Mayo Clin Proc 76, 883-889.
74. Balakrishnan M & Floch MH (2012) Prebiotics, probiotics and digestive health. Curr Opin Clin Nutr Metab Care 15, 580-585.
75. European Food Safety Authority (2010) Scientific opinion on the substantiation of a health claim related to fermented milk containing Lactobacillus casei DN-144 001 plus yoghurt symbiosis (Actimel®), and reduction of Clostridium difficile toxins in the gut of patients receiving antibiotics and reduction risk of acute diarrhoea in patients receiving antibiotics pursuant to Article 14 of Regulation (EC) No 1924/ 2006. EFSA J 8, 1903.
76. Lewis S, Burmeister S & Brazier J (2005) Effect of the prebiotic oligofructose on relapse of Clostridium difficileassociated diarrhoea: A randomized, controlled study. Clin Gastroenterol Hepatol 3, 442-448.
77. Parashar UD, Gibson CJ, Bresse JS, et al. (2006) Rotavirus and severe childhood diarrhea. Emerg Infect Dis 12, 304-316.
78. Salim AF, Phillips AD & Farthing MJ (1990) Pathogenesis of gut virus infection. Baillières Clin Gastroenterol 4, 593-607.
79. Kaila M, Isolauri E, Soppi E, et al. (1992) Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain. Pediatr Res 32, 141-144.
80. Saavedra JM, Bauman NA, Oung L, et al. (1994) Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 344, 1046-1049.
81. Sugita T & Togawa M (1994) Efficacy of Lactobacillus preparation Biolactis powder in children with rotavirus enteritis. Jpn J Pediatr 47, 2755-2762.
82. Shornnikova AV, Casas I, Mykkanen H, et al. (1997) Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis. Pediatr Infect Dis J 16, 1103-1107.
83. van Baarlen P, Troost F, Van der Meer C, et al. (2011) Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. Proc Natl Acad Sci U S A 108, 4562-4569.
84. Hilton E, Kolakowski P, Singer C, et al. (1997) Efficacy of Lactobacillus GG as a diarrheal preventive in travelers. J Travel Med 4, 41-43.
85. Oksanen PJ, Salminen S, Saxelin M, et al. (1990) Prevention of travellers' diarrhoea by Lactobacillus GG. Ann Med 22, 53-56.
86. Lyra A, Lahtinen S & Ouwehand AC (2012) Gastrointestinal benefits of probiotics: clinical evidence. In Lactic Acid Bacteria: Microbiological and Functional Aspects, pp. 509-523 [S Lahtinen, AC Ouwehand, S Salminen and A Von Wright, editors]. Boca Raton, FL: CRC.
87. McFarland LV (2007) Meta-analysis of probiotics for the prevention of traveler's diarrhea. Travel Med Infect Dis 5, 97-105.
88. Drakoularakou A, Tzortis G, Rastall RA, et al. (2010) A double-blind, placebo-controlled, randomized human study assessing the capacity of a novel galactooligosaccharide mixture in reducing traveller's diarrhoea. Eur J Clin Nutr 64, 146-152.
89. Cummings JH, Christie S & Cole TJ (2001) A study of fructo oligosaccharides in the prevention of traveller's diarrhoea. Aliment Pharmacol Ther 15, 1139-1145.
90. Virk A, Mandrekar J, Berbari EF, et al. (2013) A randomized, double blind, placebo-controlled trial of an oral synbiotic (AKSB) for prevention of traveler's diarrhea. J Travel Med 20, 88-94.
91. Vouloumanou EK, Makris GC, Karageorgopoulos DE, et al. (2009) Probiotics for the prevention of respiratory tract infections: A systematic review. Int J Antimicrob Agents 34, 197.
92. Thompson M, Vodicka TA, Blair PS, et al. (2013) Duration of symptons of respiratory tract infections in children: systematic review. BMJ 347, f7027.
93. Snow V, Mottur-Pilson C & Gonzales R (2001) American College of Physicians-American Society of Internal Medicine, American Academy of Family Physicians, Centers for Disease Control, & Infectious Diseases Society of America. Principles of appropriate antibiotic use for treatment of nonspecific upper respiratory tract infections: background. Ann Inter Med 134, 487-489.
94. Aguilar L, Giménez MJ & Barberán J (2010) Drug resistance in community-acquired respiratory tract infections: role for an emerging antibacterial. Infect Drug Resist 3, 35-43.
95. Cangemi de Gutierrez R, Santos V & Nader-Macias ME (2001) Protective effect of intranasally inoculated Lactobacillus fermentum against Streptococcus pneumoniae challenge on the mouse respiratory tract. FEMS Immunol Med Microbiol 31, 187-195.
96. Yasui H, Kiyoshima J & Hori T (2004) Reduction of influenza virus titer and protection against influenza virus infection in infant mice fed Lactobacillus casei Shirota. Clin Diagn Lab Immunol 11, 675-679.
97. Racedo S, Villena J, Medina M, et al. (2006) Lactobacillus casei administration reduces lung injuries in a Streptococcus pneumoniae infection in mice. Microbes Infect 8, 2359-2366.
98. King S, Glanville J, Sanders ME, et al. (2014) Effectiveness of probiotics on the duration of illness in healthy children and adults who develop common acute respiratory infectious conditions: A systematic review and meta-analysis. Br J Nutr 112, 41-54.
99. Arslanoglu S, Moro GE & Boehm G (2007) Early supplementation of prebiotic oligosaccharides protects formula-fed infants against infections during the first 6 months of life. J Nutr 137, 2420-2424.
100. Luoto R, Ruuskanen O, Waris M, et al. (2014) Prebiotic and probiotic supplementation prevents rhinovirus infections in preterm infants: A randomized, placebo-controlled trial. J Allergy Clin Immunol 133, 405-413.
101. Puccio G, Cajozzo C, Meli F, et al. (2007) Clinical evaluation of a new formula for infants containing live Bifidobacterium longum BL999 and prebiotics. Nutrition 23, 1-8.
102. World Health Organization (2013) Cardiovascular disease fact sheet n. 317. http://www.who.int/mediacentre/ factsheets/fs317/en/index.html (accessed February 2013).
103. Grundy SM, Cleeman JI, Merz CN, et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110, 227-239.
104. Houston MC, Fazio S, Chilton FH, et al. (2009) Nonpharmacologic treatment of dyslipidemia. Prog Cardiovasc Dis 52, 61-94.
105. Mann GV & Spoerry A (1974) Studies of a surfactant and cholesterolemia in the Maasai. Am J Clin Nutr 27, 464-469.
106. Ooi LG & Liong MT (2010) Cholesterol-lowering effects of probiotics and prebiotics: A review of in vivo and in vitro findings. Int J Mol Sci 11, 2499-2522.
107. Zhuang G, Liu XM, Zhang QX, et al. (2012) Research advances with regards to clinical outcome and potential mechanisms of the cholesterol-lowering effects of probiotics. Clin Lipidol 7, 501-507.
108. Kumar M, Nagpal R, Kumar R, et al. (2012) Cholesterollowering probiotics as potential biotherapeutics for metabolic diseases. Exp Diabetes Res 2012, Article ID 902917.
109. Davis HR Jr, Zhu LJ, Hoos LM, et al. (2004) Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem 279, 33586-33592.
110. Jeun J, Kim S, Cho SY, et al. (2010) Hypocholesterolemic effects of Lactobacillus plantarum KCTC3928 by increased bile acid excretion in C57BL/6 mice. Nutrition 26, 321-330.
111. Park YH, Kim JG, Shin YW, et al. (2007) Effect of dietary inclusion of Lactobacillus acidophilus ATCC 43121 on cholesterol metabolism in rats. J Microbiol Biotechnol 17, 655-662.
112. Agerholm-Larsen L, Raben A, Haulrik N, et al. (2000) Effect of 8 week intake of probiotic milk products on risk factors for cardiovascular diseases. Eur J Clin Nutr 54, 288-297.
113. Naruszewicz M, Johansson ML, Zapolska-Downar D, et al. (2002) Effect of Lactobacillus plantarum 299v on cardiovascular disease risk factors in smokers. Am J Clin Nutr 76, 1249-1255.
114. Ataie-Jafari A, Larijani B, Majd HA, et al. (2009) Cholesterollowering effects of probiotic yogurt in comparison with ordinary yogurt in mildly to moderately hypercholesterolemic subjects. Ann Nutr Metab 54, 22-27.
115. Jones ML, Martoni CJ, Parent M, et al. (2012) Cholesterollowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults. Br J Nutr 107, 1505-1513.
116. Bedani R, Rossi EA, Cavallini DCU, et al. (2015) Influence of daily consumption of synbiotic soy-based product supplemented with okara soybean by-product on risk factors for cardiovascular diseases. Food Res Int 73, 142-148.
117. de Roos NM, Schouten G & Katan MB (1999) Yogurt enriched with Lactobacillus acidophilus does not lower blood lipids in healthy men and women with normal to borderline high serum cholesterol levels. Eur J Clin Nutr 53, 277-280.
118. Simons LA, Armansec SG & Conway P (2006) Effect of Lactobacillus fermentum on serum lipids in subjects with elevated serum. Nutr Metab Cardiovasc Dis 16, 531-535.
119. Balcázar-Muñoz BR, Martínez-Abundis E & Gonzáles-Ortiz M (2003) Effect of oral inulin administration on lipid profile and insulin sensitivity in subjects with obesity and dyslipidemia. Revista Médica de Chile 131, 597-604.
120. Nichenametla SN, Weidauer LA, Wey HE, et al. (2014) Resistant starch type 4-enriched diet lowered blood cholesterols and improved body composition in a double blind controlled cross-over intervention. Mol Nutr Food Res 58, 1365-1369.
121. Giacco R, Clemente G, Luongo D, et al. (2004) Effects of short-chain fructo-oligosaccharides on glucose and lipid metabolism in mild hypercholesterolaemic individuals. Clin Nutr 23, 331-340.
122. Kellow NJ, Coughlan MT & Reid CM (2014) Metabolic benefits of dietary prebiotics in human subjects: A systematic review of randomised controlled trials. Br J Nutr 111, 1147-1161.
123. Rault-Nania MH, Gueux E, Demougeot C, et al. (2006) Inulin attenuates atherosclerosis in apolipoprotein E-deficient mice. Br J Nutr 96, 840-844.
124. Ranganna K, Yatsu FM, Hayes BE, et al. (2000) Butyrate inhibits proliferation-induced proliferating cell nuclear antigen expression (PCNA) in rat vascular smooth muscle cells. Mol Cell Biochem 205, 149-161.
125. Tang WH & Hazen SL (2014) The contributory role of gut microbiota in cardiovascular disease. J Clin Invest 124, 4204-4211.
126. Lavanda I, Saad SML, Lobo AR, et al. (2011) Prebióticos y su efecto en la biodisponibilidad del calcio (Prebiotics and their effect on calcium bioavailability). Revista de Nutrição 24, 333-344.
127. Pedreschi R, Campos D, Noratto G, et al. (2003) Andean yacon root (Smalllanthus sonchifolius Poepp. Endl) fructooligosaccharides as a potential novel source of prebiotics. J Agric Food Chem 51, 5278-5284.
128. Raschka L & Daniel H (2005) Mechanisms underlying the effects of inulin-type fructans on calcium absorption in the large intestine of rats. Bone 37, 728-735.
129. Kruger MC, Brown KE, Collett G, et al. (2003) The effect of fructooligosaccharides with various degrees of polymerization on calcium bioavailability in the growing rat. Exp Biol Med 228, 683-688.
130. Coxam V (2005) Inulin-type fructans and bone health: state of the art and perspectives in the management of osteoporosis. Br J Nutr 93, 111-123.
131. Lobo AR, Mancini-Filho J, Alvares EP, et al. (2009) Effects of dietary lipid composition and inulin-type fructans on mineral bioavailability in growing rats. Nutrition 25, 216-225.
132. Scholz-Ahrens KE, Ade P, Marten B, et al. (2007) Prebiotics, probiotics, and synbiotics affect mineral absorption, bone mineral content, and bone structure. J Nutr 137, 838-846.
133. van der Heuvel EG, Muijs T, Van Dokkum W, et al. (1999) Lactulose stimulates calcium absorption in postmenopausal women. J Bone Miner Res 14, 1211-1216.
134. van der Heuvel EG, Schoterman MH & Muijs T (2000) Transgalactooligosaccharides stimulate calcium absorption in postmenopausal women. J Nutr 130, 2938-2942.
135. Coudray C, Bellanger J, Castiglia-Delavaud C, et al. (1997) Effect of soluble or partly soluble dietary fibres supplementation on absorption and balance of calcium, magnesium, iron and zinc in healthy young man. Eur J Clin Nutr 51, 375-380.
136. Tahiri M, Tressol JC, Arnaud J, et al. (2003) Effect of short-chain fructooligosaccharides on intestinal calcium absorption and calcium status in postmenopausal women: A stable-isotope study. Am J Clin Nutr 77, 449-457.
137. Noack J, Dongowski G, Hartmann L, et al. (2000) The human gut bacteria Bacteroides thetaiotaomicron and Fusobacterium varium produce putrescine and spermidine in cecum of pectin-fed gnotobiotic rats. J Nutr 130, 1225-1231.
138. Bongers A & Van Den Heuvel EGHM (2003) Prebiotics and the bioavailability of minerals and trace elements. Food Rev Int 19, 397-422.
139. Scholz-Ahrens KE & Schrezenmeir J (2007) Inulin and oligofructose and mineral metabolism: The evidence from animal trials. J Nutr 137, 2513-2523.
140. Reid G (2008) Probiotic lactobacilli for urogenital health in women. J Clin Gastroenterol 42, 234-236.
141. Gardiner GE, Heinemann C, Baroja ML, et al. (2002) Oral administration of the probiotic combination Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 for human intestinal applications. Int Dairy J 12, 191-196.
142. Antonio MA, Hawes SE & Hillier SL (1999) The identification of vaginal Lactobacillus species and the demographic and microbiologic characteristics of women colonized by these species. J Infect Dis 180, 1950-1956.
143. Martin HLB, Richardson BA, Nyange PM, et al. (1999) Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis 180, 1863-1868.
144. Donders GGG, Bosmans E, Dekeersmaecker A, et al. (2000) Pathogenesis of abnormal vaginal flora. Am J Obstet Gynecol 182, 872-878.
145. McLean NW & McGroarty JA (1996) Growth inhibition of metronidazole-susceptible and metronidazole-resistant strains of Gardnerella vaginalis by lactobacilli in vitro. Appl Environ Microbiol 62, 1089-1092.
146. Reid G (2001) Probiotic agents to protect the urogenital tract against infection. Am J Clin Nutr 73, 437-443.
147. Lepargneur JP & Rousseau V (2002) Protective role of the Doderleïn flora. J Gynecol Obstet Biol Reprod 31, 485-494.
148. Valore EV, Park CH, Igreti SL, et al. (2002) Antimicrobial components of vaginal fluid. Am J Obstet Gynecol 187, 561-568.
149. Martin R, Soberon N, Vasquez F, et al. (2008) Vaginal microbiota: composition, protective role, associated pathologies, and therapeutic perspectives. Enferm Infecc Microbiol Clín 26, 160-167.
150. Reid G & Burton J (2002) Use of Lactobacillus to prevent infection by pathogenic bacteria. Microbes Infect 4, 319-324.
151. Reid G & Bocking A (2003) The potential for probiotics to prevent bacterial vaginosis and preterm labor. Am J Obstet Gynecol 189, 1202-1208.
152. Reid G & Bruce AW (2003) Urogenital infections in women: can probiotics help? J Postgrad Med 79, 428-432.
153. Reid G, Charbonneau D, Erb J, et al. (2003) Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebocontrolled trial in 64 healthy women. FEMS Immunol Med Microbiol 35, 131-134.
154. Reid G (2012) Probiotic and prebiotic applications for vaginal health. J AOAC Int 95, 31-34.
155. Bruce AW & Reid G (1988) Intravaginal instillation of lactobacilli for prevention of recurrent urinary tract infections. Can J Microbiol 34, 339-343.
156. Bruce AW, Reid G, McGroarty JA, et al. (1992) Preliminary study on the prevention of recurrent urinary tract infections in ten adult women using intravaginal lactobacilli. Int Urogynecol J 3, 22-25.
157. Martinez RCR, Franceschini SA, Patta MC, et al. (2009) Improved treatment of vulvovaginal candidiasis with fluconazole plus probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14. Lett Appl Microbiol 48, 269-274.
158. Anukam K, Osazuwa E, Ahonkhai I, et al. (2006) Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. Microbes Infect 8, 1450-1454.
159. Martinez RCR, Franceschini SA, Patta MC, et al. (2009) Improved cure of bacterial vaginosis with single dose of tinidazole (2g) and Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: A randomized, double-blind, placebo-controlled trial. Can J Microbiol 55, 133-138.
160. Williams AB, Yu C, Tashima K, et al. (2001) Evaluation of two self-care treatments for prevention of vaginal candidiasis in women with HIV. J Gen Microbiol 12, 51-57.
161. Pirotta M, Gunn J, Chondros P, et al. (2004) Effect of Lactobacillus in preventing post-antibiotic vulvovaginal candidiasis: A randomized controlled trial. BMJ 329, 548.
162. Larsson PG, Stray-Pedersen B, Ryttig KR, et al. (2008) Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebocontrolled study. BMC Womens Health 8, 3.
163. Eriksson K, Carlsson B, Forsum U, et al. (2005) A doubleblind treatment study of bacterial vaginosis with normal vaginal lactobacilli after an open treatment with vaginal clindamycin ovules. Acta Derm Venereol 85, 42-46.
164. Bizzini B, Pizzo G, Scapagnini G, et al. (2012) Probiotics and oral health. Curr Pharma Des 18, 5522-5531.
165. Selwitz RH, Ismail AI & Pitts NB (2007) Dental caries. Lancet 369, 51-59.
166. Islam B, Khan S & Khan A (2007) Dental caries: from infection to prevention. Med Sci Monit 13, 196-203.
167. Bonifait L, Chandad F & Grenier D (2009) Probiotics for oral health: myth or reality? J Can Dent Assoc 75, 585-590.
168. Ahola AJ, Yli-Knnuuttila H, Suomalainen T, et al. (2002) Short-term consumption of probiotic-containing cheese and its effect on dental caries risk factors. Arch Oral Biol 47, 799-804.
169. Nikawa H, Makihira S, Fukushima H, et al. (2004) Lactobacillus reuteri in bovine milk fermented decreases the oral carriage of mutans streptococci. Int J Food Microbiol 95, 219-223.
170. Kang MS, Chung J, Kim SM, et al. (2006) Effect of Weissella cibaria isolates on the formation of Streptococcus mutans biofilm. Caries Res 40, 418-425.
171. Houle MA & Grenier D (2003) Maladies parodontales: connaissances actuelles (Current concepts in periodontal diseases). Méd Maladies Infect 33, 331-340.
172. Sookkhee S, Chulasiri M & Prachyabrued W (2001) Lactic acid bacteria from healthy oral cavity of Thai volunteers: inhibition of oral pathogens. J Appl Microbiol 90, 172-179.
173. Koll-Klais P, Mandar R, Leibur E, et al. (2005) Oral lactobacilli in chronic periodontitis and periodontal health: species composition and antimicrobial activity. Oral Microbiol Immunol 20, 354-361.
174. Krasse P, Carisson B, Dahl C, et al. (2006) Decreased gum bleeding and reduced gingivitis by the probiotic Lactobacillus reuteri. Swed Dent J 30, 55-60.
175. Riccia DN, Bizzini F, Perilli MG, et al. (2007) Anti-inflammatory effects of Lactobacillus brevis (CD2) on periodontal disease. Oral Dis 13, 376-385.
176. Laleman I & Teughels W (2015) Probiotics in the dental practice: A review. Quintessence Int 46, 255-264.
177. Scully C & Greenman J (2008) Halitosis (breath odor). Periodontology 48, 66-75.
178. Burton JP, Chicott CN & Tagg JR (2005) The rationale and potential for the reduction of oral malodour using Streptococcus salivarius probiotics. Oral Dis 11, 29-31.
179. Keller MK, Bardow A, Jensdottir T, et al. (2012) Effect of chewing gums containing the probiotic bacterium Lactobacillus reuteri on oral malodour. Acta Odontol Scand 70, 246-250.
180. Schabussova I & Wiedermann U (2008) Lactic acid bacteria as novel adjuvant systems for prevention and treatment of atopic diseases. Curr Opin Allergy Clin Immunol 8, 557-564.
181. Penders J, Stobberingh EE, Van Den Brandt PA, et al. (2007) The role of the intestinal microbiota in the development of atopic disorders. Allergy 62, 1223-1236.
182. Prescott SL & Bjorksten B (2007) Probiotics for the prevention or treatment of allergic diseases. J Allergy Clin Immunol 120, 255-262.
183. Bjorksten B, Sepp E, Julge K, et al. (2001) Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol 108, 516-520.
184. Kalliomaki M, Kirjavainen P, Eerola E, et al. (2001) Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not dveloping. J Allergy Clin Immunol 107, 129-134.
185. Sepp E, Julge K, Mikelsaar M, et al. (2005) Intestinal microbiota and immunoglobulin E responses in 5-year-old Estonian children. Clin Exp Allergy 35, 1141-1146.
186. Kukkonen K, Savilahti E, Haahtela T, et al. (2007) Probiotics and prebiotic galactooligosaccharides in the prevention of allergic diseases: A randomized, double-blind, placebocontrolled trial. J Allergy Clin Immunol 119, 192-198.
187. Marschan E, Kuitunen M, Kukkonen K, et al. (2008) Probiotics in infancy induce protective immune profiles that are characteristic for chronic low-grade inflammation. Clin Exp Allergy 38, 611-618.
188. Rautava S, Kalliomaki M & Isolauri E (2002) Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against topic disease in the infant. J Allergy Clin Immunol 109, 119-121.
189. Kopp MV, Hennemuth I, Heinzmann A, et al. (2008) Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: no clinical effects of Lactobacillus GG supplementation. Pediatrics 121, 850-856.
190. Kim SO, Ah YM, Yu YM, et al. (2014) Effects of probiotics for the treatment of atopic dermatitis: A meta-analysis of randomized controlled trials. Ann Allergy Asthma Immunol 113, 217-226.
191. Martinez-Canavate A, Sierra S, Lara-Villoslada F, et al. (2009) A probiotic dairy product containing L. gasseri CECT5714 and L. coryniformis CEC5711 induces immunological changes in children suffering from allergy. Pediatr Allergy Immunol 20, 592-600.
192. Majamaa H & Isolauri E (1997) Probiotics: A novel approach in the management of food allergy. J Allergy Clin Immunol 99, 179-185.
193. Isolauri E, Rautava S, Kalliomaki M, et al. (2002) Role of probiotics in food hypersensitivity. Curr Opini Allergy Clin Immunol 2, 263-271.
194. Osborn DA & Sinn JKH (2009) Probiotics in infants for prevention of allergic disease and food hypersensitivity. Cochrane Database of Systematic Reviews, issue 4, CD006475, http://onlinelibrary.wiley.com/doi/10.1002/ 14651858.CD006475.pub2/epdf.
195. Wells JM & Mercenier A (2008) Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol 6, 349-362.
196. Sashihara T, Sueki N & Ikegami S (2006) An analysis of the effectiveness of heat-killed lactic acid bacteria in alleviating allergic diseases. J Dairy Sci 89, 2846-2855.
197. Medina M, Izquierdo E, Ennahar S, et al. (2007) Differential immunomodulatory properties of Bifidobacterium longum strains: relevance to probiotic selection and clinical applications. Clin Exp Immunol 150, 531-538.
198. Kekkonen RA, Kajasto E, Miettinen M, et al. (2008) Probiotic Leuconostoc mesenteroides spp. cremoris and Streptococcus thermophilus induce IL-2 and IFN-gamma production. World J Gastroenterol 14, 1192-1203.
199. Foligne B, Zoumpopoulou G, Dewulf J, et al. (2007) A key role of dendritic cells in probiotic functionality. PLoS ONE 2, e313.
200. Blander JM & Medzhitov R (2006) Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440, 808-812.
201. Fujiwara D, Inoue S, Wakabayashi H, et al. (2004) The antiallergic effects of lactic acid bacteria are strain dependent and mediated by effects on both Th1/Th2 cytokine expression and balance. Int Arch Allergy Immunol 135, 205-215.
202. Kalliomäki M, Antoine JM, Herz U, et al. (2010) Guidance for substantiating the evidence for beneficial effects of probiotics: prevention and management of allergic diseases by probiotics. J Nutr 140, 713-721.
203. Niele N, van Zwol A, Westerbeek EAM, et al. (2013) Effect of non-human neutral and acidic oligosaccharides on allergic and infectious diseases in preterm infants. Eur J Pediatr 172, 317-323.
204. Schouten B, Van Esch BC, Kormelink TG, et al. (2011) Non-digestible oligosaccharides reduce immunoglobulin free light-chain concentrations in infants at risk for allergy. Pediatr Allergy Immunol 22, 537-542.
205. Williams HC & Grindlay DJ (2010) What's new in atopic eczema? An analysis of systematic reviews published in 2007 and 2008. Part 1: definitions, causes and consequences of eczema. Clin Exp Dermatol 35, 12-15.
206. Osborn DA & Sinn JKH (2013) Prebiotics in infants for prevention of allergy. Cochrane Database of Systematic Reviews, issue 28, CD006474. http://onlinelibrary.wiley.com/doi/ 10.1002/14651858.CD006474.pub3/epdf.
207. Jonkers D, Penders J, Masclee A, et al. (2012) Probiotics in the management of inflammatory bowel disease. Drugs 72, 803-823.
208. Kawada M, Arihiro A & Mizoguchi E (2007) Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease. World J Gastroenterol 13, 5581-5593.
209. Abraham C & Medzhitov R (2011) Interaction between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology 140, 1729-1737.
210. Danese S (2011) Immune and nonimmune components orchestrate the pathogenesis of inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 300, 716-722.
211. Dignass A, Van Assche G, Lindsay JO, et al. (2010) The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohn's Colitis 4, 28-62.
212. Lebeer S, Vanderleyden J & De Keersmaecker SC (2008) Genes and molecules of lactobacilli supporting probiotic action. Microbiol Mol Biol Rev 72, 728-764.
213. Oelschlaeger TA (2010) Mechanisms of probiotics actions-A review. Int J Med Microbiol 300, 57-62.
214. Borchers AT, Selmi V, Meyers FJ, et al. (2009) Probiotics and immunity. J Gastroenterol 44, p. 26-46.
215. Caballero-Franco C, Keller K, De Simone C, et al. (2007) The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol 291, 315-322.
216. Karczewski J, Troost FJ, Konings I, et al. (2010) Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier. Am J Physiol Gastrointest Liver Physiol 298, 851-859.
217. Ng SC, Plamondon S, Kamm MA, et al. (2010) Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis. Inflamm Bowel Dis 16, 1286-1298.
218. Rahimi R, Nikfar S, Rahimi F, et al. (2008) A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig Dis Sci 53, 2524-2531.
219. Shen J, Zuo ZX & Mao AP (2014) Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis 20, 21-35.
220. Rijkers GT, Bengmark S, Enck P, et al. (2010) Guidance for substantiating the evidence for beneficial effects of probiotics: current status and recommendations for future research. J Nutr 140, 671-676.
221. Moayyedi P, Ford AC, Talley NJ, et al. (2010) The efficacy of probiotics in the treatment of irritable bowel syndrome: A systematic review. Gut 59, 325-332.
222. Spiller R, Aziz Q, Creed F, et al. (2007) Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 56, 1770-1798.
223. Clarke G, Cryan JF, Dinan TG, et al. (2012) Review article: probiotics for the treatment of irritable bowel syndrome-focus on lactic acid bacteria. Aliment Pharmcol Ther 35, 403-413.
224. Brenner DM, Moeller MJ, Chey WD, et al. (2009) The utility of probiotics in the treatment of irritable bowel syndrome: A systematic review. Am J Gastroenterol 104, 1033-1049.
225. Parkes GC, Sanderson JD & Whelan K (2010) Treating irritable bowel syndrome with probiotics: The evidence. Proc Nutr Soc 69, 187-194.
226. Horvath A, Dziechciarz P & Szajewska H (2011) Metaanalysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood. Aliment Pharmcol Ther 33, 1302-1310.
227. Ringel Y & Ringel-Kulka T (2011) The rationale and clinical effectiveness of probiotics in irritable bowel syndrome. J Clin Gastroenterol 45, 145-148.
228. Whelan K (2014) The importance of systematic reviews and meta-analyses of probiotics and prebiotics. Am J Gastroenterol 109, 1563-1565.
229. Haller D, Antoine JM, Bengmark S, et al. (2010) Guidance for substantiating the evidence for beneficial effects of probiotics: probiotics in chronic inflammatory bowel disease and the functional disorder irritable bowel syndrome. J Nutr 140, 690-697.
230. O'Mahony L, Mccarthy J, Kelly P, et al. (2005) Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128, 541-551.
231. Whorwell PJ, Altringer L, Morel J, et al. (2006) Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 101, 1581-1590.
232. Bonfrate L, Tack J, Grattagliano I, et al. (2013) Microbiota in health and irritable bowel syndrome: current knowledge, perspectives and therapeutic options. Scand J Gastroenterol 48, 995-1009.
233. Hunter JO, Tuffnell Q & Lee AJ (1999) Controlled trial of oligofructose in the management of irritable bowel syndrome. J Nutr 129, 1451-1453.
234. Olesen M & Gudmand-Hoyer E (2000) Efficacy, safety, and tolerability of fructooligosaccharides in the treatment of irritable bowel syndrome. Am J Clin Nutr 72, 1570-1575.
235. Silk DBA, Davis A, Vulevic J, et al. (2009) Clinical trial: The effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmcol Ther 29, 508-518.
236. Andriulli A, Neri M, Loguercio C, et al. (2008) Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: A multicenter, randomized study. J Clin Gastroenterol 42, 218-223.
237. Guandalini S, Cernat E & Moscoso D (2015) Prebiotics and probiotics in irritable bowel syndrome and inflammatory bowel disease in children. Benef Microbes 6, 209-217.
238. Floch MH (2014) Recommendations for probiotic use in humans-A 2014 update. Pharmaceuticals 7, 999-1007.
239. Lesbros-Pantoflickova D, Corthesy-Theulaz I & Blum AL (2007) Helicobacter pylori and probiotics. J Nutr 137, 812-818.
240. Michetti P, Dorta G, Wiesel PH, et al. (1999) Effect of wheybased culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Digestion 60, 203-209.
241. Ruggiero P (2014) Use of probiotics in the fight against Helicobacter pylori. World J Gastrointest Pathophysiol 5, 384-391.
242. Felley CP, Corthesy-Theulaz I, Rivero JL, et al. (2001) Favourable effect of an acidified milk (LC-1) on Helicobacter pylori gastritis in man. Eur J Gastroenterol Hepatol 13, 25-29.
243. Pantoflickova D, Corthesy-Theulaz I, Dorta G, et al. (2003) Favorable effect of long-term intake of fermented milk containing Lactobacillus johnsonii on H. pylori associated gastritis. Aliment Pharmacol Ther 18, 805-813.
244. Wang KY, Li SN, Liu CS, et al. (2004) Effects of ingesting Lactobacillus-and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori. Am J Clin Nutr 80, 737-741.
245. Lionetti E, Miniello VL, Castellaneta SP, et al. (2006) Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: A randomized placebo controlled trial. Aliment Pharmacol Ther 24, 1461-1468.
246. Francavilla R, Polimeno L, Demichina A, et al. (2014) Lactobacillus reuteri strain combination in Helicobacter pylori infection-A randomized, double-blind, placebocontrolled study. J Clin Gastroenterol 48, 407-413.
247. Yang YJ, Chuang CC, Yang HB, et al. (2012) Lactobacillus acidophilus ameliorates H. pylori induced gastric inflammation by inactivating the Smad7 and NFκB pathways. BMC Microbiol 12, 38.
248. Chen X, Liu XM, Tian F, et al. (2012) Antagonistic activities of lactobacilli against Helicobacter pylori growth and infection in human gastric epithelial cells. J Food Sci 77, 9-14.
249. Navarro-Rodriguez T, Silva FM, Barbuti RC, et al. (2013) Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: A randomized, double-blind, placebo-controlled study. BMC Gastroenterol 13, 56.
250. Szajewska H, Horvath A & Piwowarczyk A (2010) Meta-analysis: The effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 32, 1069-1079.
251. Zhang MM, Qian W, Qin YY, et al. (2015) Probiotics in Helicobacter pylori eradication therapy: A systematic review and meta-analysis. World J Gastroenterol 21, 4345-4357.
252. Katan MB (2012) Why the European Food Safety Authority was right to reject health claims on probiotics. Benef Microbes 3, 85-89.
253. Glanville J, King S, Guarner F, et al. (2015) A review of the systematic review process and its applicability for use in evaluating evidence for health claims on probiotic foods in the European Union. J Nutr 14, 16.
254. Bisanz JE, Enos MK, Mwanga JR, et al. (2014) Randomized open-label pilot study of the influence of probiotics and the gut microbiome on toxic metal levels in Tanzanian pregnant women and school children. MBio 5, e01580-14.